TEVAR 2016: Companies Push New Frontiers In Thoracic Aortic Interventions
Executive Summary
Although thoracic endovascular aortic repair (TEVAR) is now routine for lesions like dissection of the descending aorta, the Big Three aortic endovascular companies are developing devices for the more technically challenging proximal and distal portions of the thoracic aorta while physicians refine TEVAR in the descending aorta. Insiders say endovascular techniques are overcoming limitations and physicians will soon be able to treat the entire aorta, from the aortic valve to the bifurcation.
You may also be interested in...
EVAR Update: Companies Target Complex Anatomies With Innovative Solutions
As endovascular aortic repair (EVAR) becomes a mainstream procedure, companies are racing to develop products that can treat patients with more challenging anatomy. As the space bubbles with ongoing trials and new-product launches, newer companies hope to make their mark in a space dominated by the established market leaders Medtronic PLC, Cook Medical Inc. and WL Gore & Associates.
‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals
Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.
Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims
US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.